

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Grow Brian</u> (Last) (First) (Middle) <u>C/O ORGANOGENESIS HOLDINGS INC.</u> <u>85 DAN ROAD</u> (Street) <u>CANTON MA 02021</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Organogenesis Holdings Inc. [ORGO]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Commercial Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>12/10/2018</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/10/2018		A		1,462	A	(1)	1,462	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$1.7	12/10/2018		A		667		(2)	10/02/2019	Common Stock	667	(3)	667	D	
Stock Option (Right to Buy)	\$1.7	12/10/2018		A		1,151		(2)	04/15/2020	Common Stock	1,151	(4)	1,151	D	
Stock Option (Right to Buy)	\$1.44	12/10/2018		A		958		(2)	10/17/2021	Common Stock	958	(5)	958	D	
Stock Option (Right to Buy)	\$1.46	12/10/2018		A		805		(2)	08/21/2022	Common Stock	805	(6)	805	D	
Stock Option (Right to Buy)	\$4.49	12/10/2018		A		805		(2)	07/17/2023	Common Stock	805	(7)	805	D	
Stock Option (Right to Buy)	\$1.24	12/10/2018		A		958		(2)	01/12/2025	Common Stock	958	(8)	958	D	
Stock Option (Right to Buy)	\$2.47	12/10/2018		A		4,060		(9)	08/11/2025	Common Stock	4,060	(10)	4,060	D	
Stock Option (Right to Buy)	\$1.18	12/10/2018		A		30,450		(11)	04/10/2024	Common Stock	30,450	(12)	30,450	D	
Stock Option (Right to Buy)	\$3.46	12/10/2018		A		102,200		(13)	05/04/2027	Common Stock	102,200	(14)	102,200	D	
Stock Option (Right to Buy)	\$3.46	12/10/2018		A		60,900		(15)	05/04/2027	Common Stock	60,900	(16)	60,900	D	

Explanation of Responses:

1. Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for 720 shares of common stock of Organogenesis.

2. 100% of the shares subject to this option are fully vested and exercisable.
3. Received in connection with the Merger in exchange for an option to acquire 329 shares of common stock of Organogenesis for \$3.45 per share.
4. Received in connection with the Merger in exchange for an option to acquire 567 shares of common stock of Organogenesis for \$3.45 per share.
5. Received in connection with the Merger in exchange for an option to acquire 472 shares of common stock of Organogenesis for \$2.92 per share.
6. Received in connection with the Merger in exchange for an option to acquire 397 shares of common stock of Organogenesis for \$2.95 per share.
7. Received in connection with the Merger in exchange for an option to acquire 397 shares of common stock of Organogenesis for \$9.10 per share.
8. Received in connection with the Merger in exchange for an option to acquire 472 shares of common stock of Organogenesis for \$2.50 per share.
9. The shares underlying the option vested or shall vest 25% annually beginning on August 11, 2016.
10. Received in connection with the Merger in exchange for an option to acquire 2,000 shares of common stock of Organogenesis for \$5.00 per share.
11. The shares underlying the option vested or shall vest 20% annually beginning on April 1, 2015.
12. Received in connection with the Merger in exchange for an option to acquire 15,000 shares of common stock of Organogenesis for \$2.38 per share.
13. The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017.
14. Received in connection with the Merger in exchange for an option to acquire 50,345 shares of common stock of Organogenesis for \$7.01 per share.
15. The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018.
16. Received in connection with the Merger in exchange for an option to acquire 30,000 shares of common stock of Organogenesis for \$7.01 per share.

Remarks:

/s/ Stacie S. Aarestad, Attorney- 12/12/2018
in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.